The number of cytology cases has been increasing over time in Korea \[[@b1-jptm-2017-08-11]\]. In 1988, the Papanicolaou (Pap) smear was first introduced to screen for cervical cancer during regular health check-ups for Korean industrial workers and their family members \[[@b2-jptm-2017-08-11]\]. The National Cancer Screening Program for stomach, breast and cervical cancer began in 1999. Over time, participation in this program has increased as both the target population and the cancer types included have expanded \[[@b2-jptm-2017-08-11]\]. Recent guidelines for cervical cancer screening in Korea recommend that all asymptomatic women over the age of 20 begin cervical cancer screening with a Pap smear or liquid-based cytology (LBC) and continue every 3 years until the age of 74 (if three-consecutive cytologic examinations have been negative within the previous 10 years) \[[@b3-jptm-2017-08-11]\].

The Korean Society for Cytopathology is committed to improving the quality of cytologic diagnosis and guiding the administration and management of cytology laboratories. The Committee for Quality Improvement (QI), founded in 1992, monitors and evaluates cytopathologic outcomes on a regular basis. This committee has generated standard operating procedures and documents for quality assurance/quality control since 1995; this is the same year that the first nationwide survey for quality control in cytopathology was conducted \[[@b1-jptm-2017-08-11]\]. Cytology proficiency testing has been performed as a part of QI programs since 1996. Every year since 2003, all cytopathology laboratories have been required to submit the previous year's quality control statistics and participate in two cytology proficiency testing programs as provided by the QI committee \[[@b1-jptm-2017-08-11]\]. The QI program has contributed to a reduction in cervical cancer mortality, reducing the odds ratio to 0.36 (95% confidence interval, 0.31 to 0.43) \[[@b3-jptm-2017-08-11]\].

In this study, we present nationwide cytology statistics from 2015, including the number of cytology cases, specimen type, case volume by diagnosis, specimen preparation methods, and cytology-histology correlations.

MATERIALS AND METHODS
=====================

The QI Committee of the Korean Society for Cytopathology conducted a nationwide quality control survey in cytopathology from February 2, 2016, to February 22, 2016. The questionnaire was sent to 208 medical institutions performing cytopathologic examinations in Korea in order to gather statistical data on cytology and gynecologic (GYN) cytology-histology correlation results from 2015. Written informed consent was obtained from each institution. This study was approved by the Institutional Review Board of The Catholic University of Korea, Seoul St. Mary's Hospital (KC13SISI0198).

For the purposes of this study, medical institutions were categorized into three groups: university hospitals, general hospitals, and commercial laboratories. All cytology samples were also classified into three groups: GYN, fine needle aspiration (FNA), and non-GYN/non-FNA samples including body fluids, urine, bronchial washing/brushing samples, cerebrospinal fluid, etc. The diagnostic concordance between cytologic and corresponding histologic examinations of the uterine cervix was categorized as either concordant (category O) or into one of three discordant categories: category A (minimal clinical impact), category B (moderate clinical impact), and category C (major clinical impact). The criteria for the assessment of diagnostic accuracy are shown in [Table 1](#t1-jptm-2017-08-11){ref-type="table"}.

Statistical analysis was performed using GraphPad Prism software ver. 6.05 (GraphPad Software, La Jolla, CA). p-values less than .05 were considered statistically significant. Graphs were generated using GraphPad Prism and Microsoft Excel.

RESULTS
=======

Responses were obtained from 206 out of 208 medical institutions (99.0%) including 83 university hospitals, 87 general hospitals, and 36 commercial laboratories.

Statistics of all cytopathology cases in 2015
---------------------------------------------

The total number of cytopathologic examinations performed in 2015 was 8,284,952, of which 5,717,336 (69.0%) were performed in commercial laboratories, 1,603,591 (19.4%) in university hospitals, and 964,025 (11.6%) in general hospitals ([Fig. 1A](#f1-jptm-2017-08-11){ref-type="fig"}).

Out of a total of 8,284,952 samples examined, 6,734,465 (81.3%) were classified as GYN, 314,893 (3.8%) as FNA, and 1,235,594 (14.9%) as non-GYN/non-FNA ([Fig. 1B](#f1-jptm-2017-08-11){ref-type="fig"}).

In all, 6,190,526 (74.7%) cytology samples were prepared for conventional smear (CS) and 2,094,426 (25.3%) were prepared for LBC. Among the CS samples, 81.2% were GYN, 3.5% were FNA, and 15.3% were non-GYN/non-FNA. Among the LBC samples, 81.5% were GYN, 4.7% were FNA, and 13.9% were non-GYN/non-FNA ([Fig. 1C](#f1-jptm-2017-08-11){ref-type="fig"}).

Statistics of GYN cytology
--------------------------

The number of GYN cytology samples was 6,734,465. GYN cytology samples were examined mainly at commercial laboratories (74.9%, n = 5,043,280) and followed by university hospitals (13.9%, n = 935,590) and general hospitals (11.2%, n = 755,595) ([Fig. 2A](#f2-jptm-2017-08-11){ref-type="fig"}).

GYN cytology samples in commercial laboratories and general hospitals were more frequently examined by CS than LBC, whereas university hospitals preferred LBC over CS ([Fig. 2B](#f2-jptm-2017-08-11){ref-type="fig"}).

Statistics of FNA cytology
--------------------------

A total of 314,893 FNA cytology samples were examined. Among them, 133,849 (42%) were examined in commercial laboratories, 125,059 (40%) in university hospitals, and 55,985 (18%) in general hospitals ([Fig. 3A](#f3-jptm-2017-08-11){ref-type="fig"}).

The most common specimens were thyroid followed by lung ([Fig. 3B](#f3-jptm-2017-08-11){ref-type="fig"}). FNA Samples in university hospitals showed the highest ratio of LBC to CS followed by general hospitals and commercial laboratories in descending order ([Fig. 3C](#f3-jptm-2017-08-11){ref-type="fig"}).

Statistics of non-GYN, non-FNA cytology
---------------------------------------

A total of 1,235,594 non-GYN/non-FNA cytology samples were examined, consisting of 542,942 (43.9%) from university hospitals, 540,207 (43.7%) from commercial laboratories, and 152,445 (12.3%) from general hospitals ([Fig. 4A](#f4-jptm-2017-08-11){ref-type="fig"}). The proportion of each specimen type (respiratory, body fluid, urine, cerebrospinal fluid, etc.) is shown in [Fig. 4B](#f4-jptm-2017-08-11){ref-type="fig"}. The most common type of non-GYN/non-FNA specimen was respiratory cytology, regardless of the type of institution. The ratio of LBC to CS was higher in university and general hospitals than in commercial laboratories ([Fig. 4C](#f4-jptm-2017-08-11){ref-type="fig"}).

Methods of LBC preparation
--------------------------

A total of 11 methods for LBC preparation were used: ThinPrep (Hologic, Marlborough, MA, USA), Cell Prep (Biodyne, Seongnam, Korea), SurePath (BD Diagnostics, Sparks, MD, USA), Huro Path (CelltraZone, Seoul, Korea), MonoPrep (MonoGen, Arlington Heights, IL, USA), Prex-Prep, EASY Prep (YD Diagnostics, Yongin, Korea), Cell Scan (Cell & Tech Bio, Seoul, Korea), CYTO-fast (Hospitex Diagnostics, Firenze, Italy), Liqui-PREP (LGM International, Melbourne, FL, USA), and Max-Prep ([Fig. 5](#f5-jptm-2017-08-11){ref-type="fig"}). The number of medical institutions using each type of LBC preparation method is listed here in descending order: ThinPrep (68), SurePath (44), Cell Prep (17), EASY Prep (9), Huro Path (5), Cell Scan (4), and Prex-Prep (2). Only one institution used a preparation other than the aforementioned methods. The most commonly used LBC method was ThinPrep (39.7%) followed by Cell Prep (26.3%) and SurePath (23.7%); the others methods accounted for less than 5% of LBC cases. In GYN cytology specimens, ThinPrep (38.8%) was most commonly used followed by Cell Prep (30.0%) and SurePath (19.4%). In non-GYN/non-FNA cytology specimens, SurePath (49.9%) was most commonly used followed by ThinPrep (44.7%) and Cell Prep (2.6%). In FNA cytology specimens, ThinPrep (45.0%) was most commonly used followed by SurePath (33.6%), EASY Prep (12.9%), and Huro Path (4.5%).

Prevalence of cytologic diagnoses of the uterine cervix
-------------------------------------------------------

Of the GYN cytology samples, 95% were diagnosed as negative, 3% as atypical squamous cells of undetermined significance (ASCUS), and 1% as low-grade squamous intraepithelial lesion (LSIL). In each type of institution, 1% of samples were considered to be unsatisfactory. The frequencies of unsatisfactory, negative, ASCUS, atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesion, atypical glandular cells (AGC), AGC-favor neoplastic, LSIL, high-grade squamous intraepithelial lesion, adenocarcinoma *in situ*, squamous cell carcinoma, adenocarcinoma, etc. are shown in [Table 2](#t2-jptm-2017-08-11){ref-type="table"}.

The ratio of atypical squamous cells of undetermined significance to squamous intraepithelial lesion (ASCUS:SIL), representing the screening sensitivity, was significantly higher in commercial laboratories (6.0 ± 9.2) than in university hospitals (1.9 ± 2.0) and general hospitals (2.8 ± 3.0) (p \< .001) ([Fig. 6](#f6-jptm-2017-08-11){ref-type="fig"}).

Diagnostic accuracy of GYN cytology
-----------------------------------

Statistical data on diagnostic accuracy were obtained from 77 university hospitals and 54 general hospitals ([Fig. 7](#f7-jptm-2017-08-11){ref-type="fig"}). In university hospitals, a total of 44,044 GYN cytology cases were compared with matching histologic specimens with the following results: 9.1% in category A, 4.0% in category B, 0.6% in category C, and 86.3% in category O. In general hospitals, a total of 3,898 GYN cytology cases were compared with matching histologic specimens with the following results: 17.4% in category A, 10.2% in category B, 1.9% in category C, and 69.5% in category O. Accuracy data from commercial laboratories was not available.

DISCUSSION
==========

The survey response rate for this study was quite high. In all, 99.0% of medical institutions providing cytopathology service responded to this survey as mandated by the QI program of the Korean Society for Cytopathology.

GYN cytology comprised 81.3% of all cases, which is due to the national cervical cancer screening program. Of the GYN cytology samples, 74.9% were examined at commercial laboratories, 13.9% at university hospitals, and 11.2% at general hospitals. In Korea, Pap smears are generally performed in primary care clinics and health promotion centers, and most of those specimens are then sent to commercial laboratories.

The conventional Pap smear is a simple and effective method for screening cervical cancer. LBC was initially introduced in GYN cytology, and its use has increased continuously over the past two decades. According to a previous nationwide study in Korea, the use of LBC comprised 7.6% and 20.5% of all cytology cases in 2004 and 2007, respectively ([Fig. 8](#f8-jptm-2017-08-11){ref-type="fig"}) \[[@b1-jptm-2017-08-11]\]. In 2015, LBC was used in 25.3% of all GYN cytology cases. In university hospitals, 55.9% of all GYN cytology were examined by LBC, whereas commercial laboratories used LBC less frequently ([Fig. 2B](#f2-jptm-2017-08-11){ref-type="fig"}).

In the field of non-GYN cytology, LBC is only used for body fluid and thyroid aspiration samples by the National Health Insurance System in Korea. The proportion of LBC in non-GYN cytology cases was higher in university hospitals than in other types of institutions ([Figs. 3C](#f3-jptm-2017-08-11){ref-type="fig"}, [4C](#f4-jptm-2017-08-11){ref-type="fig"}). The thyroid gland was the highest source of FNA samples ([Fig. 3B](#f3-jptm-2017-08-11){ref-type="fig"}). The high number of thyroid FNA cases in Korea closely correlates with the high rate of thyroid cancer screening, as Korea has the highest incidence of thyroid cancer in the world \[[@b4-jptm-2017-08-11]\]. Although 11 methods of LBC were introduced in Korea, more than 95% of cases used either ThinPrep, Cell Prep, or SurePath. This is the first report to investigate the current status of the LBC methods used in Korea.

The overall rates of unsatisfactory, negative, and ASCUS for GYN cytology cases were 0.6%, 94.6%, and 3.5% respectively. These results did not significantly differ among the three types of medical institutions. The ASCUS rate may have varied according to the cytopathologist performing the exam. The ASCUS:SIL ratio was less affected than the ASCUS rate by patient population, prevalence of disease, and the effect of screening \[[@b5-jptm-2017-08-11]-[@b10-jptm-2017-08-11]\]. Thus, the ASCUS:SIL ratio was used as a quality control reference \[[@b10-jptm-2017-08-11]\]. In one study, cytotechnologists with an ASCUS:SIL ratio \< 1.5 showed a significantly lower sensitivity than those with a ratio \> 3.0.5 In our study, the mean ASCUS:SIL ratio was 1.9 in university hospitals, 2.8 in general hospitals, and 6.0 in commercial laboratories ([Fig. 6](#f6-jptm-2017-08-11){ref-type="fig"}). Thus, the mean screening sensitivity of commercial laboratories may be higher when compared with referral hospitals.

Quality control of diagnostic accuracy was assessed by correlating cervical cytology with histologic results as mandated in university hospitals and general hospitals by the QI program of the Korean Society for Cytopathology. However, this correlation was not performed in most commercial laboratories. The concordance rate of cytologic and histologic diagnoses may vary depending upon the time difference between the two examinations \[[@b11-jptm-2017-08-11]-[@b13-jptm-2017-08-11]\]. Diagnostic correlations between cytology and histology are lower when the two examinations are performed simultaneously than when cytology precedes histologic examination \[[@b11-jptm-2017-08-11],[@b12-jptm-2017-08-11]\]. During this study, we recognized that there was no standardization of cytologic-histologic correlation methods, including the type of histologic specimens, the intervals for correlation, and the statistical metrics used. In our study, cytologic-histologic correlation was performed in real time and/or retrospectively. The tissue samples for histologic correlation were obtained from either cervical biopsy, conization, or hysterectomy.

We found that the volume of cytology cases, sample type, preparation method, access to paired tissue specimens, practice variables, and screening sensitivity all differed from institution to institution. In general, both the total volume of cytology cases and the proportion of cases using LBC have significantly increased. The screening sensitivity of GYN cytology was higher and more variable in commercial laboratories when compared with university and general hospitals. The results of this study can serve as basic data for the establishment of nationwide cytopathology policies and QI guidelines in Korean medical institutions.
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###### 

Assessment of diagnostic accuracy in cervical cytology

  Histologic diagnosis        Cytologic diagnosis                         Category
  --------------------------- ------------------------------------------- ----------
  Squamous cell                                                           
   Negative                   Negative                                    O
                              ASCUS                                       A
                              ASC-H                                       B
                              LSIL                                        B
                              HSIL                                        C
                              Squamous cell carcinoma                     C
   LSIL                       Negative                                    B
                              ASCUS                                       A
                              ASC-H                                       A
                              LSIL                                        O
                              HSIL                                        B
                              Squamous cell carcinoma                     B
   HSIL                       Negative                                    C
                              ASCUS                                       B
                              ASC-H                                       A
                              LSIL                                        B
                              HSIL                                        O
                              Squamous cell carcinoma                     A
   Squamous cell carcinoma    Negative                                    C
                              ASCUS                                       C
                              ASC-H                                       B
                              LSIL                                        B
                              HSIL                                        A
                              Squamous cell carcinoma                     O
  Glandular cell                                                          
   Negative                   Negative                                    O
                              Atypical glandular cells                    A
                              Atypical glandular cells favor neoplastic   B
                              Endocervical adenocarcinoma *in situ*       C
                              Adenocarcinoma                              C
   Adenocarcinoma *in situ*   Negative                                    B
                              Atypical glandular cells                    A
                              Atypical glandular cells favor neoplastic   A
                              Endocervical adenocarcinoma *in situ*       O
                              Adenocarcinoma                              A
   Adenocarcinoma             Negative                                    C
                              Atypical glandular cells                    B
                              Atypical glandular cells favor neoplastic   B
                              Endocervical adenocarcinoma *in situ*       A
                              Adenocarcinoma                              O
  Other                                                                   
   Other malignant neoplasm   Negative                                    C
                              ASCUS                                       B
                              ASC-H                                       B
                              LSIL                                        B
                              HSIL                                        A
                              Squamous cell carcinoma                     A
                              Atypical glandular cells                    B
                              Atypical glandular cells favor neoplastic   A
                              Endocervical adenocarcinoma *in situ*       A
                              Adenocarcinoma                              A

ASCUS, atypical squamous cells of undetermined significance; ASC-H, atypical squamous cells ca nnot exclude high-grade squamous intraepithelial lesion; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion.

###### 

Prevalence of cytologic diagnosis of uterine cervix according to the type of medical institution

  Cytology                   University hospital   Commercial laboratory   General hospital   Total
  -------------------------- --------------------- ----------------------- ------------------ ------------------
  Unsatisfactory             5,010 (0.5)           30,271 (0.7)            5,421 (0.7)        40,702 (0.6)
  Negative                   872,873 (93.6)        4,382,832 (94.7)        741,720 (95.5)     5,997,425 (94.6)
  ASCUS                      29,421 (3.2)          171,549 (3.7)           20,224 (2.6)       221,194 (3.5)
  ASC-H                      3,792 (0.4)           6,640 (0.1)             1,504 (0.2)        11,936 (0.2)
  LSIL                       13,262 (1.4)          28,667 (0.6)            5,253 (0.7)        47,182 (0.7)
  HSIL                       5,243 (0.6)           6,010 (0.1)             1,833 (0.2)        13,086 (0.2)
  Squamous cell carcinoma    890 (0.1)             500 (\< 0.1)            246 (\< 0.1)       1,636 (\< 0.1)
  AGC                        1,055 (0.1)           2,350 (0.1)             507 (0.1)          3,912 (0.1)
  AGC, favor neoplastic      195 (\< 0.1)          292 (\< 0.1)            74 (\< 0.1)        561 (\< 0.1)
  Adenocarcinoma *in situ*   51 (\< 0.1)           4 (\< 0.1)              19 (\< 0.1)        74 (\< 0.1)
  Adenocarcinoma             348 (\< 0.1)          65 (\< 0.1)             64 (\< 0.1)        477 (\< 0.1)
  Others                     56 (\< 0.1)           628 (\< 0.1)            13 (\< 0.1)        697 (\< 0.1)
  Total                      932,196 (100)         4,629,808 (100)         776,878 (100)      6,338,882 (100)

Values are presented as number (%).

ASCUS, atypical squamous cells of undetermined significance; ASC-H, atypical squamous cells cannot exclude high-grade squamous intraepithelial lesion; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion; AGC, atypical glandular cells.
